期刊文献+

41例服用华法林老年患者国际标准化比值异常变化的药物因素 被引量:8

Drug Factors in Unusual Change of International Normalized Ratio: A Study of 41 Cases of Elderly Patients Taking Warfain
下载PDF
导出
摘要 目的探讨引起服用华法林老年患者国际标准化比值(INR)异常变化的药物因素和机制,为老年患者安全有效使用华法林提供指导。方法回顾分析华中科技大学同济医学院附属同济医院2011—2015年监测发现INR异常变化的41例服用华法林老年住院患者的住院资料。结果 41例中INR异常升高37例(90.2%),INR异常下降4例(9.8%);静脉药物(80.5%)更易导致INR异常变化;前列地尔(26.8%)、抗真菌药(29.3%)、抗心律失常药(29.3%)、脂溶性维生素(9.8%)是引起INR异常变化的常见药物。结论服用华法林老年患者在住院期间易出现药源性凝血功能的异常变化,联用其他药物时应加强INR监测,安全有效抗凝。 ObjectiveTo investigate the unusual drug induced International Normalized Ratio(INR)change in elderly patients with warfarin treatment and its related mechanism.MethodsA retrospective analysis was performed in41cases of elderly patients with unusual drug induced INR change from2011to2015in Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology.ResultsINR was increased unusually in37cases(90.2%)and was decreased unusually in4cases(9.8%).Intravenous drugs(80.5%)were prone to cause unusual INR change.Prostaglandin,antifungal drugs,antiarrhythmic drugs and lipid soluble vitamins were the commonly used drugs that induced adverse reaction,accounting for26.8%,29.3%,29.3%and9.8%,respectively.ConclusionUnusual drug induced INR change is not rare in elderly patients with warfarin treatment during hospitalization.When other drugs are prescribed,INR should be measured more frequently and the dose of warfarin should be adjusted promptly.
作者 肖幸 周仑 高翔 张存泰 凃玲 XIAO Xing;ZHOU Lun;GAO Xiang;ZHANG Cuntai;TU Ling(Department of Geriatrics,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,China)
出处 《医药导报》 CAS 北大核心 2018年第1期107-109,共3页 Herald of Medicine
关键词 华法林 国际标准化比值 不良反应 药物 患者 老年 Warfarin International Normalized Ratio Adverse drug reaction Patient, elderly
  • 相关文献

参考文献7

二级参考文献63

  • 1韩军,肖成华.麦滋林联合弥可保防治XELOX腹泻及神经毒性30例观察[J].青海医药杂志,2012,42(12):11-12. 被引量:1
  • 2吴文静,柯元南.华法林与氯沙坦、非诺贝特及别嘌醇伍用致上消化道出血[J].药物不良反应杂志,2005,7(1):59-60. 被引量:3
  • 3胡大一,张鹤萍,孙艺红,姜立清.华法林与阿司匹林预防非瓣膜性心房颤动患者血栓栓塞的随机对照研究[J].中华心血管病杂志,2006,34(4):295-298. 被引量:162
  • 4Hirsh J, Fuster V, Ansell J, et al. American Heart Association/ American College of Cardiology Foundation guide to warfarin therapy. J Am Coil Cardiol, 2003,41:1633-1652.
  • 5Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 2007, 146:S57-867.
  • 6Hu D, Sun Y. Epidemiology, risk factors for stroke, and management of atrial fibrillation in China. J Am Coil Cardiol, 2008, 52: 865-868.
  • 7Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med, 2005,352:2285-2293.
  • 8Aithal GP, Day CP, Kesteven PJ, et al. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, 1999, 353:717-719.
  • 9Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :eddS- 88S.
  • 10Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141 (2 Suppl) :e152S-184S.

共引文献639

同被引文献99

引证文献8

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部